We have located links that may give you full text access.
The emergence of metronidazole and vancomycin reduced-susceptibility in Clostridium difficile isolates in Iran.
Journal of Global Antimicrobial Resistance 2019 January 29
OBJECTIVES: Clostridium difficile is the main causative agent of antibiotic-associated diarrhoea (AAD) and pseudomembranous colitis (PMC). The accumulation of antimicrobial resistance in C. difficile strains can drive Clostridium difficile infection (CDI) epidemiology. This study was undertaken in order to evaluate the antimicrobial resistance patterns of toxigenic C. difficile isolates cultured from diarrhoeal stool samples of hospitalised patients with suspected CDI in three tertiary care hospitals in Tehran, Iran.
METHODS: Two hundred and fifty diarrhoeal stool samples were investigated by toxigenic culture using cycloserine-cefoxitin-fructose agar and the VERO cell line. Antimicrobial susceptibility to metronidazole, vancomycin, clindamycin, tetracycline, and moxifloxacin was performed by disk diffusion and E-test methods on Brucella Blood Agar supplemented with hemin and vitamin K.
RESULTS: Thirty-five stool samples (14.0%) proved positive using C. difficile toxigenic culture. According to CLSI breakpoints, the following resistance was identified in C. difficile isolates: metronidazole (2/35); moxifloxacin (7/35); clindamycin (18/35); and tetracycline (5/35). Using EUCAST breakpoints, 3/35 isolates showed reduced-susceptibility for vancomycin and 14/35 for metronidazole. In addition, the results showed a good correlation between the inhibition zone diameter (disk diffusion) and MIC values (E-test); Pearson correlation coefficient 0.7400.95, P<0.001.
CONCLUSIONS: Multidrug resistance was observed in Iranian clinical toxigenic C. difficile isolates, including reduced-susceptibility to first-line CDI treatment drugs. I addition, disk diffusion can be used as cost-effective option for the antimicrobial susceptibility testing of C. difficile isolates.
METHODS: Two hundred and fifty diarrhoeal stool samples were investigated by toxigenic culture using cycloserine-cefoxitin-fructose agar and the VERO cell line. Antimicrobial susceptibility to metronidazole, vancomycin, clindamycin, tetracycline, and moxifloxacin was performed by disk diffusion and E-test methods on Brucella Blood Agar supplemented with hemin and vitamin K.
RESULTS: Thirty-five stool samples (14.0%) proved positive using C. difficile toxigenic culture. According to CLSI breakpoints, the following resistance was identified in C. difficile isolates: metronidazole (2/35); moxifloxacin (7/35); clindamycin (18/35); and tetracycline (5/35). Using EUCAST breakpoints, 3/35 isolates showed reduced-susceptibility for vancomycin and 14/35 for metronidazole. In addition, the results showed a good correlation between the inhibition zone diameter (disk diffusion) and MIC values (E-test); Pearson correlation coefficient 0.7400.95, P<0.001.
CONCLUSIONS: Multidrug resistance was observed in Iranian clinical toxigenic C. difficile isolates, including reduced-susceptibility to first-line CDI treatment drugs. I addition, disk diffusion can be used as cost-effective option for the antimicrobial susceptibility testing of C. difficile isolates.
Full text links
Related Resources
Trending Papers
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Systemic lupus erythematosus.Lancet 2024 April 18
Should renin-angiotensin system inhibitors be held prior to major surgery?British Journal of Anaesthesia 2024 May
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Colorectal polypectomy and endoscopic mucosal resection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2024.Endoscopy 2024 April 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app